Workspaces
Log in Sign up

Eli Lilly Commands Q2 2026 with Blockbuster Earnings: Tirzepatide Surges as Oral Foundayo Misses Slightly

Updated

Sources

Eli Lilly Commands Q2 2026 with Blockbuster Earnings: Tirzepatide Surges as Oral Foundayo Misses Slightly

Eli Lilly & Co. delivered an exceptionally strong financial performance in Q2 2026, crushing Wall Street expectations and raising its full-year guidance. The company's massive growth continues to be powered by its blockbuster injectable tirzepatide franchise (Mounjaro and Zepbound), offsetting a slight sales miss for its newly launched oral obesity pill, Foundayo (orforglipron).

Massive Q2 Revenue Blowout

Eli Lilly's second-quarter results solidified its position as the dominant force in the cardiometabolic drug market. Driven by unprecedented demand for its GLP-1/GIP co-agonist therapies, Lilly's revenue grew at a staggering rate.

According to BioPharma Dive:

"Lilly, meanwhile, crushed Wall Street expectations with its results on Wednesday, RBC Capital Markets analyst Trung Huynh wrote in a note to clients. Second-quarter revenue jumped 48% to almost $23 billion, beating a consensus estimate of $20.6 billion. Lilly credited the continued growth of tirzepatide, the world’s best-selling drug, which is marketed as Mounjaro for diabetes and Zepbound for obesity."

This blowout performance stands in stark contrast to its main competitor, Novo Nordisk, which faced a 6% stock drop following clinical and commercial setbacks in the same week.

Guidance Raised on Injectable Dominance

Following the massive earnings beat, Eli Lilly raised its full-year revenue guidance, reflecting high confidence in the ongoing commercial expansion of its injectable portfolio.

According to BioPharma Dive:

"Lilly said its revenue should reach between $85 billion and $87 billion for the year, up from an estimate of $82 billion to $85 billion."

The tirzepatide franchise has established clear market leadership in the U.S. obesity and diabetes segments, capitalizing on Novo Nordisk's capacity constraints and pricing pressures.

Oral Foundayo Launch Performance

While Lilly's injectables dominated, its oral obesity offering, Foundayo (orforglipron), faced a minor commercial speed bump. The daily oral small-molecule GLP-1 receptor agonist, which was approved by the FDA in April 2026, missed Wall Street consensus estimates.

According to BioPharma Dive:

"Foundayo sales also fell short of Wall Street expectations in the quarter, coming in at $98 million versus a consensus estimate of $104 million1, per RBC’s Huynh. But Lilly may be benefiting from lower expectations that are built in at this point for its pill. Certainly, investors were unperturbed by the report Wednesday, sending shares of the Indianapolis-based drugmaker 2% higher in early trading."

Despite the slight miss, Foundayo represents a key strategic asset for Lilly, as it does not require cold-chain distribution or complex biologic manufacturing, positioning it for long-term global expansion.

  1. An instance of Oral weight-loss formulations cannot replicate the commercial momentum of their injectable predecessors. — Despite massive expectations for non-peptide small molecules, Eli Lilly's daily oral pill Foundayo missed early commercial forecasts. ↩︎

Part of

This finding is an example of a pattern recurring across your work:

Backlinks

Revision history

  • Update note to capture Eli Lilly's blowout Q2 2026 earnings, 48% YoY revenue surge to $23B, raised full-year guidance, and Foundayo's early commercial results.
    · by the agent
  • Updated to reflect Eli Lilly's overall market share dominance (59.5%), the muted launch of Foundayo relative to oral Wegovy, and the major generic tirzepatide ANDA filings by Sandoz and Hybio Pharmaceutical.
    · by the agent
  • Update the Eli Lilly note to integrate the June 2026 Gallup survey, Q1 2026 tirzepatide sales, Foundayo's early launch numbers, and Medicare Bridge program pricing.
    · by the agent
  • Update Foundayo note to record the sNDA submission in Type 2 diabetes by the end of Q2 2026 based on Phase 3 ACHIEVE data, and include the FDA's demands for post-marketing safety studies.
    · by the agent
  • Update the Foundayo launch note to include the massive clinical data presented at ADA 2026 for Type 2 diabetes (ACHIEVE trials), the head-to-head superiority over oral semaglutide and Farxiga, and plans for the upcoming sNDA submission.
    · by the agent
  • Update Foundayo note with the June 2026 ADA Phase 3 ACHIEVE trial data in Type 2 Diabetes and upcoming FDA submission.
    · by the agent
  • Updated without a stated reason.
    · by migration